A cost-analysis of suspected adverse drug reactions in a hospital emergency ward

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 7, 1999, Pages 529-534

  Ayani, I ^a,b   Aguirre, C ^a   Gutierrez G ^c   Madariaga, A ^a   Rodriguez SasianN J M ^c   Martinez Bengoechea M J ^c  

^a Pharmacovigilance Centre   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c NONE

Author keywords

Adverse drug reaction reporting systems; Adverse effect; Cost analysis; Hospital surveillance

Indexed keywords

DRUG;

ABDOMINAL RADIOGRAPHY; ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BIOCHEMISTRY; BLOOD CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; COST OF ILLNESS; DRUG SURVEILLANCE PROGRAM; EMERGENCY WARD; ENDOSCOPY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SKIN DISEASE; TEACHING HOSPITAL; THORAX RADIOGRAPHY;

EID: 0033367661     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199912)8:7<529::AID-PDS460>3.0.CO;2-J     Document Type: Article

References (19)

1. Stoukides, C. A., D'Agostino, P. R. and Kaufman, M. B. Adverse drug reaction surveillance in an emergency room. Am. J. Hosp. Pharm. 1993; 50: 712-714.
2. Ibáñez, L., Laporte, J. R. and Carné, X. Adverse drug reactions leading to hospital admission. Drug Safety 1991; 6: 450-459.
3. McKenzie, M. W., Marchall, G. L., Netzloff, M. L., Cluff, L. E. Adverse drug reactions leading to hospitalisation in children. J. Pediatr. 1976; 89: 487-490.
4. Prince, B. S., Goetz, C. M., Rihn, T. L. and Olsky, M. Drug-related emergency department visits and hospital admissions. Am. J. Hosp. Pharm. 1992; 49: 1696-1700.
5. Einarson, T. R. Drug-related hospital admissions. Ann. Pharmacother. 1993; 27: 832-840.
6. Basskin, L. How to collect and analyze costs associated with adverse drug events. Formulary 1996; 31: 399-403.
7. Basskin, L. How to target adverse drug events using cost-benefits analysis. Formulary 1996; 31: 507-514.
8. Moore, N., Briffaut, C., Noblet, C., Normand, C. A. and Thuillz, C. Indirect drug-related costs. Lancet 1995; 345: 588-589.
9. Schneider, P. J., Gift, M. G., Lee, Y. P., Rothermich, E. A. and Sill, B. E. Cost of medication-related problems at a university hospital. Am. J. Health-Syst. Pharm. 1995; 52: 2415-2418.
10. Edwards, J. A. M. The financial cost of an adverse drug reaction: a case study. Aust. J. Hosp. Pharm. 1988; 18: 407-409.
11. Johnson, J. A. and Bootman, J. L. Drug-related morbidity and mortality. A cost-of-illness model. Arch. Intern. Med. 1995; 155: 1949-1956.
12. Mignot, G., Biaggi, J., Lethurgez, P. and Chichmanian, R. M. Analyse financière des hospitalisations pour effets indésirables. Therapie 1990; 45: 387-390.
13. Ayani, I., Gutiérrez, G., Alonso, J. et al. Comparison of two pharmacosurveillance methods applied in a hospital emergency room. Therapie 1995; S1: 174.
14. Muñoz, M. J., Ayani, I., Rodríguez-Sasiain, J. M., Gutiérrez, G. and Aguirre, C. Monitorización en un servicio de urgencias de reacciones adversas causadas por medicamentos en adultos y ninos. Med. Clin. (Barc.) 1998; 111: 92-98.
15. Requirements for Adverse Drug Reaction Reporting, World Health Organization, Geneva, 1975.
16. Pearson, T. F., Pittman, D. G., Longley, J. M., Grapes, T., Vigliotti, D. J. and Mullis, S. R. Factors associated with preventable adverse drug reactions. Am. J. Hosp. Pharm. 1994; 51: 2268-2272.
17. Henry, D., Lim, L. L. Y., García Rodríguez, L. A. et al. Variability in risk of gastrointestinal coḿ plications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br. Med. J. 1996; 312: 1563-1566.
18. Roth, S. H. NSAID gastropathy. A new understanding. Arch. Intern. Med. 1996; 156: 1623-1628.
19. de Pouvourville, G. Preventing NSAID-induced gastrointestinal toxicity. Economical considerations, methodological problems and results. Pharmacoeconomics 1995; 7: 99-110.